by Diana Swift: For More Info, Go Here..
Treatment with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) was associated with a “rapid and significant” decrease in risk for all-cause mortality and hepatocellular carcinoma (HCC), a French prospective study found.
“Taking a large cohort like this provides the opportunity to evaluate the effect of direct-acting antiviral therapy on the long-term outcomes of patients with hepatitis C,” Carrat said in a news release. “We saw a reduction of risk for complications related to the disease, and to mortality, and believe this treatment should be considered for all patients with chronic hepatitis C infection.”